The project management is responsible for the content of the information provided.
This project, funded by Gebert Rüf Stiftung, is supported by the following project partners: University of Bern, NCCR TransCure, Innosuisse, BaseLaunch, Venture Kick, Horizon2020 programme (SME Instrument)
Förderbeitrag: CHF 150'000
Dauer: 08.2019 - 10.2020
InnoBooster, seit 2018
Inst. of Biochemistry & Molecular Medicine
3012 Bern (Schweiz)
- firstname.lastname@example.org. ch
Neuropsychiatric disorders are still one of the highest unmet medical needs in human medicine. The major problem is lack of innovation and urgent need for of safe and effective drugs for these disorders.
Synendos develops an innovative approach based upon first-in-class inhibitors. The inhibitors were designed and developed at the University of Bern starting from an in silico screening of 12 million compounds followed by a thorough medicinal chemistry programme. In total, 800 purchasable and newly synthetized compounds were tested leading to the selection of the preclinical drug candidate at the end of 2018.
Our mission at Synendos is to advance the development of this new class of inhibitors and provide a more safe and effective therapy for unmet needs in neuropsychiatric disorders.
Was ist das Besondere an diesem Projekt?
At Synendos, we develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders. Our first-in-class inhibitors enables restoration of natural functioning of the brain through the modulation of a new drug target (not yet published), which was recently identified at the University of Bern after 8 years of basic research.
Unlike current drugs, our inhibitors offer a potential superior safety profile for short and long term use and an improved therapeutic control of the symptoms associated to neuropsychiatric disorders. These effects can be achieved thanks to an innovative self-limiting mechanism of action that mildly but effectively restores the natural functioning of different neuronal circuits. Thanks to this pro-homeostatic effect on neurotransmission and neuronal plasticity, our inhibitors have the potential to become the first effective treatment for unmet needs in neuropsychiatric disorders with enormous benefit for patients, healthcare providers, communities and society.
We recently identified our preclinical drug candidate with two possible follow up/back up compounds after a thorough medicinal chemistry programme. Synendos is going to advance the development of the drug candidate with preclinical safety and efficacy studies followed by human trials.
The identification of the new drug target enables Synendos to optimize a drug discovery platform to identify new generation inhibitors and expand its pipeline.
In our next steps we aim to close the first financing round with investors to accelerate preclinical development of the drug candidate, enable starting first-in-human study and expand the team of Synendos.
Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, Gertsch J. The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors. Front Mol Neurosci. 2018 May 28; 11:180.
Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Aparisi Rey A, Petrucci V, Reynoso-Moreno IDC, Viveros-Paredes JM, Dalghi Gens M, Lutz B, Schiöth HB, Soeberdt M, Abels C, Charles RP, Altmann KH, Gertsch J. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A. 2017 Jun 20;114(25): E5006-E5015.
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 11.02.2020